Citations

Clear

16280 citation(s) found for "Yu, David".

Tau exacerbates the development of distinct neuropsychiatric symptoms in late braak stage – the head study
Amaral, Lívia , Zalzale, Hussein, Abbas, Sarah , Tudorascu, Dana , Lowe, Val J. , Oh, Hwamee , Soleimani‐Meigooni, David N. , Baker, Suzanne L. , Aguzzoli, Cristiano Schaffer , Povala, Guilherme , Ferreira, Pâmela C.L. , Lussier, Firoza Zubeida , Bauer‐Negrini, Guilherme , Soares, Carolina , Ferrari‐Souza, João Pedro , Bellaver, Bruna , Rohden, Francieli , Leffa, Douglas Teixeira , Schilling, Lucas Porcello , Zimmer, Eduardo Rigon , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.092310 Get It

AbstractBackgroundRecent studies showed that neuroinflammation plays a key role in triggering specific neuropsychiatric symptoms (NPS), such as irritability and agitation, in individuals with Alzheimer’s disease (AD). While prior studies showed an association between tau pathology and all NPS domains, the extent to which tau influences each specific NPS domain remains unclear. Here, we aim to investigate the association of tau and NPS domains in the AD continuum. We hypothesize that tau plays a comparatively greater effect on the emergence of psychotic symptoms compared to other NPS domains.MethodWe assessed 56 individuals (21 cognitively unimpaired (CU), 23 MCI, and 12 AD dementia) from the HEAD study who underwent clinical assessments with the Neuropsychiatry Inventory Questionnaire (NPI‐Q) and had positron emission tomography (PET) for amyloid‐β (Aβ) ([18F]AZD4694 or [11C]PiB), and tau tangles ([18F]MK6240) at the same visit. We selected individuals with an NPI‐Q total score ≥1. Tau SUVR values were tailored with a mask from Braak stages I‐VI, using the inferior cerebellar gray matter as reference region. Leave‐one‐out voxel wise and linear regression tested the association between each NPI‐Q domain and biomarkers accounting for age, sex, cognitive status, and study site.ResultCI individuals had significantly higher NPI‐Q score and Braak VI PET SUVR than CU individuals (Table 1). NPI‐Q score was significantly associated with tau‐PET in the periRolandic and supplementary motor cortex (Figures 1A). Linear regression showed that NPI‐Q associates with tau‐PET in the Braak stage VI (Figure 1B). Leave‐one‐out regression analysis revealed that delusions, motor disturbances, and anxiety contributed most to the association between tau‐PET and NPS (Figure 2A, C). These domains presented a higher magnitude of association compared to each other NPI‐Q domain (Figure 2B). Notably, irritability, agitation, and disinhibition exerted a negative effect to the association, emphasizing that tau may not play a role in the development of these symptoms (Figure 2A, D)ConclusionOur study supports previous evidence suggesting that irritability and agitation may not be triggered by tau, but rather by other pathological process such as neuroinflammation. These findings provide additional rationale for the therapeutics aiming to mitigate irritability and agitation in AD patients.
Development of a composite score to predict Lewy body pathology burden
Zhang, Nan , Belden, Christine M. , Adler, Charles, Shill, Holly A. , Mehta, Shyamal H. , Driver‐Dunckley, Erika, Beach, Thomas G. , Reiman, Eric M., Choudhury, Parichita , Chen, Kewei , Tremblay, Cécilia , Ho, Andrew, Driver‐Dunckley, Erika , Shprecher, David , Serrano, Geidy E. , Reiman, Eric M. , Atri, Alireza

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.092056 Get It

AbstractBackgroundLewy body (LB) diseases can present with overlapping prodromal, cognitive, motor, autonomic or neuropsychiatric symptoms. Intuitively, greater symptom severity should correlate with greater pathological burden, but this has not been consistently shown. LB pathology does not translate to clinical expression in Incidental LB disease. While several composite scores/toolkits utilize overlapping schemes for diagnosis, a composite data‐derived score to predict LB pathologic burden is lacking. We aimed to utilize an autopsy‐confirmed cohort, and validated, brief, and standardized clinical, functional, pathologic assessments, and machine learning (ML)/quantitative modeling techniques to identify clusters and importance rankings among assessments/measures to predict LB pathologic severity and density.MethodA total of 234 subjects with neuropathological finding of LB at autopsy in the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) who were classified as Cognitively Unimpaired or Mild Cognitive Impairment after their first study clinical evaluation were included. Of these, 145 subjects had complete scores for 32 of 46 measures (clinical, cognitive, behavioral and functional) that were utilized as predictors of LB pathology. Olfactory function was assessed using the University of Pennsylvania Smell Identification Test (UPSIT). LB severity was assessed by the Unified Staging System for Lewy Body Disorders (USSLB). Several ML algorithms and quantitative prediction models were explored and compared: artificial neural network (ANN), partial least square regression (PLSR), support vector regression (SVR), relevance vector regression (RVR) and ensemble forest regression (EFR) with leave‐one‐out (LOO) scheme. Game‐theory based Shapley methods assessed the impact, including rankings, consistency and magnitude, of model predictors.ResultRVR predicted aggregate LB density with large effect size (R2 = 0.691, p<0.00001). ANN predicted USSLB severity stage with large effect size (R2 = 0.74, p<2.5e‐43). All other ML algorithms/models provided substantial prediction. Across all models, UPSIT was the most influential predictor (>65%), followed by Controlled Oral Word Association Test (COWAT) and age.ConclusionThese preliminary and exploratory results support the utilization of ML techniques/models to assess LB pathologic burden with key measures collected in relatively small samples. UPSIT was consistently ranked highest impactful among clinical and functional measures/predictors. Integrated together in ML/data‐derived composites, UPSIT, COWAT and other clinical characteristics may be of antemortem utility to predict USSLB stages.
Longitudinal variability in resting heart rate associates with empathy decline in pre‐symptomatic and symptomatic familial frontotemporal degeneration
Massimo, Lauren , Heuer, Hilary W. , Boxer, Adam L. , Rosen, Howard J. , Rankin, Katherine P. , Sturm, Virginia E. , (ALLFTD), ARTFL‐LEFFTDS, Rhodes, Emma , Dratch, Laynie , Irwin, David J. , Boeve, Bradley F. , McMillan, Corey T. , (ALLFTD), ARTFL‐LEFFTDS

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.091893 Get It

AbstractBackgroundAutonomic dysfunction has been linked to empathy deficits in symptomatic frontotemporal degeneration (FTD), but less is known about pre‐symptomatic FTD mutation carriers (preFTD+). Our prior work found that increasing resting heart rate (RHR) over time predicts decline in emotional empathy in preFTD+. Here, we replicate previous findings in a large, multi‐site consortium sample and assess relationships between RHR and empathy loss across disease stages.MethodRHR and Interpersonal Reactivity Index (IRI) were obtained serially for up to 7 years in 348 preFTD+, 202 symptomatic FTD mutation carriers (FTD+), and 311 non‐carrier family members (FTD‐) enrolled in ALLFTD. IRI Perspective Taking (IRI‐PT) and Empathic Concern (IRI‐EC) subscales measured cognitive and emotional empathy, respectively. Separate multiple linear regressions related mutation status and annualized change in RHR to annualized change in IRI subscales and assessed interactions between RHR change and phenoconversion status among mutation carriers. Logistic regression was used to assess the association between change in RHR and phenoconversion among mutation carriers, and Wilcoxon signed‐rank tests were used to examine differences in change in RHR between all study groups.ResultIn asymptomatic participants (preFTD+ and FTD‐), increase in RHR over time was associated with greater decline in IRI‐EC (ß = ‐0.07, p<.001) and IRI‐PT (ß = ‐0.03, p = .011), regardless of mutation status. Among mutation carriers (preFTD+ and FTD+), increase in RHR was associated with greater decline in IRI‐EC (ß = ‐0.04, p = .041), and this effect was stronger in FTD+ compared to PreFTD+ (ß = ‐0.07, p = .038), while an increase in RHR was associated with decline in IRI‐PT only in FTD+ (ß = ‐0.07, p = .046). Change in RHR did not predict phenoconversion in mutation carriers (PreFTD+ and FTD+), but PreFTD+ showed less change in RHR over time relative to FTD+.ConclusionChanges in empathy in asymptomatic preFTD+ and FTD‐ are linked to variability in RHR regardless of genetic status, likely reflecting a non‐specific impact of autonomic functioning on empathy and prosocial behavior. In contrast, increasing RHR predicts decline in cognitive and emotional empathy in FTD mutation carriers but primarily after phenoconversion, suggesting that autonomic contributions to empathy in familial FTD increase with disease progression and could be an early marker of manifest disease.
Remote Naturalistic Speech Analysis as a Tool to Classify Behavioral Variant Frontotemporal Dementia
Vonk, Jet M. J. , Morin, Brittany , Dhanam, Sreya, Clark, Annie L , Young, Jacob , Taylor, Jack C. , Rosado‐Rolon, David, Heuer, Hilary W. , Forsberg, Leah K. , Rosen, Howard J. , Tempini, Maria Luisa Gorno , Boxer, Adam L. , Staffaroni, Adam M. , Dhanam, Sreya , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.091734 Get It

AbstractBackgroundFrontotemporal dementia (FTD) is a diverse spectrum of neurodegenerative disorders impacting the frontal and temporal lobes, primarily manifesting as behavioral and/or language issues. Accurate diagnosis is crucial for effective management, potential treatment, and care planning. While speech analysis has shown promise in detecting cognitive markers of Alzheimer’s disease (AD), its exploration in FTD is limited. This study examined if linguistic features from remote, app‐based speech collection can differentiate healthy controls (HC) from individuals with behavioral variant FTD (bvFTD), the most common FTD variant.MethodParticipants included 15 bvFTD (mean age = 64.3, SD = 9.1 years) and 19 HC (mean = 55.8, SD = 14.2) from the ALLFTD Consortium. Participants were prompted to talk freely about a happy memory; audio recordings were collected with the ALLFTD Mobile App, transcribed using OpenAI’s large Whisper model, and manually quality‐checked. We extracted 98 linguistic features using our in‐house pipeline (Fig 1). Features were selected for classification analysis if they differed between groups based on a MANCOVA adjusted for age, sex/gender, and education, with feature reduction in case of collinearity. We then determined if these features could classify groups using multi‐variable logistic regression models, and subsequently calculated its ROC‐AUC score to measure sensitivity/specificity.ResultBased on the MANCOVA, three features were selected for classification analysis: average seconds of non‐speech (i.e., silence), ratio of number of complex nominal clauses to total clauses, and number of restarts (i.e., disfluency). The logistic model showed that this set could distinguish between groups (Omnibus p = .001; Nagelkerke R2 = .499), and their saved prediction probabilities indicated a ROC‐AUC score of 84.8% accuracy (Fig 2).ConclusionLeveraging a flexible speech capture app with remote accessibility and state‐of‐the‐art automated speech analysis, we identified linguistic features that can distinguish HC from bvFTD. This approach presents a promising screening tool for detecting bvFTD, offering quick, easily administered assessments with the potential for scalable implementation outside of clinical settings. Next steps are to investigate linguistic changes in presymptomatic mutation carriers and compare speech profiles between FTD and AD. These results hold meaningful implications for addressing current challenges in FTD therapeutics, potentially offering sensitive outcome measures for clinical trials and future tools for personalized cognitive assessment and long‐term monitoring.
Accuracy of intact performance on measures of odor identification, global cognition, and amyloid imaging for identifying lack of cognitive decline and dementia in the Mayo Clinic Study of Aging cohort
Motter, Jeffrey N. , Lee, Seonjoo, Vassilaki, Maria , Devanand, Davangere P. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.088601 Get It

AbstractBackgroundPrevious studies have linked impaired odor identification and global cognition with increased risk of cognitive decline and transition to dementia. However, the reverse question remains: if individuals have intact performance on these measures, are they at reduced risk for transition? We aimed to examine the accuracy of intact odor identification and global cognition for identifying lack of transition to dementia/cognitive decline using the population‐based Mayo Clinic Study of Aging and compare their accuracy against and in combination with amyloid PET (Positron Emission Tomography).Methodn = 647 participants age≥55 without dementia completed at baseline the Brief Smell Identification Test (BSIT; ‘Intact’ = 9‐12), Blessed Information‐Memory‐Concentration Test (BIMCT; ‘Intact’ = 18‐20,), and amyloid PET (‘Normal/Intact’ SUVR<1.48). We calculated sensitivity, specificity, positive predictive value, and negative predictive value for these measures, with “lack of transition to dementia” as the gold standard/target. “Lack of cognitive decline” (cognitively unimpaired to mild cognitive impairment [MCI]; cognitively unimpaired to dementia; or MCI to dementia) was a secondary target.Result94.7% of participants (613/647) did not transition to dementia and 84.2% (545/647) did not cognitively decline over 11.25‐year‐follow‐up. The combination of intact BSIT+BIMCT had high rates of lack of transition to dementia (98.3%, 355/361) and lack of cognitive decline (93.1%, 336/361). This combination yielded mixed sensitivity (0.579) and specificity (0.824) though had high positive predictive value (0.983) for identifying lack of transition to dementia. Intact amyloid PET alone exhibited comparable rates of lack of transition to dementia (99.0%, 418/423) and lack of cognitive decline (92.4%, 391/423). When evaluated conjointly, the combination of all three intact measures also had mixed sensitivity (0.421) and specificity (0.962) though higher positive predictive value (PPV = 0.996) for lack of transition to dementia. 99.6% (258/259) of participants with intact/normal status on all three did not transition to dementia and 96.5% (250/259) did not cognitively decline.ConclusionThis replicates prior reports that intact olfaction/global cognition have strong utility for identifying individuals unlikely to develop MCI/dementia. Intact/normal amyloid PET further enhances the positive predictive value. Clinically, identifying individuals at low risk of transition can shorten diagnostic workups, reduce need for early follow‐up visits, and screen patients in‐or‐out of clinical trials.
Effect of hearing intervention on three‐year change in brain morphology
Huang, Alison , Reed, Nicholas S. , Burgard, Sheila , Gmelin, Theresa , Gravens‐Mueller, Lisa, Albert, Marilyn S. , Lin, Frank R., Pike, James Russell , Deal, Jennifer A. , Chisolm, Theresa Hnath , Couper, David , Glynn, Nancy W. , Goman, Adele M. , Hayden, Kathleen M. , MITCHELL, CHRISTINE M. , Pankow, James S. , Sanchez, Victoria A , Schrack, Jennifer A. , Jack, Clifford R. , Knopman, David S. , Coresh, Josef , Lin, Frank R.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.086740 Get It

AbstractBackgroundPrior longitudinal studies among older adults have documented associations between hearing loss and changes in brain morphology. Whether interventions involving hearing aids can reduce age‐related atrophy is unknown. A substudy within the Aging and Cognitive Health Evaluation in Elders (ACHIEVE, Clinicaltrials.gov Identifier: NCT03243422) randomized controlled trial tested the effect of a best‐practices hearing intervention versus health education control on three‐year change in cortical thickness among older adults with hearing loss.MethodThe ACHIEVE study enrolled 977 community‐dwelling adults aged 70‐84 years at baseline (2018‐2019) with untreated hearing loss (better ear pure tone average [0.5‐4 kHz] ≥30 and <70 dB HL) and without substantial cognitive impairment from four sites across the U.S. (Jackson, MS, Forsyth County, NC, Minneapolis, MN, Washington County, MD). Participants were randomized to a hearing intervention (provision of hearing aids and related technologies, counseling, and education) or a health education control (individual sessions with a health educator covering topics relevant to chronic disease and disability prevention). Three‐dimensional magnetic resonance imaging was performed on 3 Tesla Siemens scanners in a subsample of 445 participants at the ACHIEVE baseline and three‐year follow‐up. Linear mixed effects models were used in intention‐to‐treat analyses to estimate three‐year change in cortical thickness. All models adjusted for baseline measures of hearing loss, recruitment source, site, age, sex, and education. Missing outcome and covariate data was imputed to mitigate bias caused by informative attrition.ResultAt baseline, 224 participants were women (50.3%), 52 participants were Black (11.7%), and the mean (SD) age was 76.4 (4.0) years old (Table 1). Compared to the health education control, the hearing intervention exhibited a nominally protective effect on three‐year change in average cortical thickness (Figure 1). The greatest effect size for cortical thickness was observed in the occipital lobe, while the smallest effect size was detected in the temporal lobe. Statistically significant effects were detected in the pars orbitalis, rostral anterior cingulate, posterior cingulate, and isthmus cingulate (Figure 2).ConclusionHearing aid use may reduce decline in cortical thickness among older adults. The effects of hearing aids may be greatest in regions other than those associated with the auditory cortex.
Mayo Normative Studies: regression‐based normative data for remote self‐administration of the Stricker Learning Span, Symbols Test and Mayo Test Drive Screening Battery Composite for ages 33‐100 and validation in MCI and dementia
Frank, Ryan D. , Fan, Winnie Z. , Christianson, Teresa J., Stricker, John L. , Lucas, John A. , Graff‐Radford, Jonathan, Petersen, Ronald C. , Stricker, Nikki H. , Boots, Elizabeth A. , Kremers, Walter K. , Machulda, Mary M. , Hassenstab, Jason , Graff‐Radford, Jonathan , Vemuri, Prashanthi , Jack, Clifford R. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.085612 Get It

AbstractBackgroundFew normative data for computerized measures administered in unsupervised remote environments are available. We aimed to determine what variables to include in normative models for remote self‐administered assessments, develop normative data for measures administered through Mayo Test Drive (MTD, a multi‐device remote cognitive assessment platform) and evaluate application of norms.Method1240 adults ages 33‐100 (96% White) from the Mayo Clinic Study of Aging and Mayo Alzheimer’s Disease Research Center met normative sample inclusion criteria that included a concordant Cognitively Unimpaired (CU) diagnosis (3 independent raters all diagnosed CU) and CDR = 0 (see Table 1 for sample characteristics). Raw test scores were converted to normalized scaled scores. We derived regression‐based normative data that adjusted for age, age2, sex and education (base model); alternative models are also provided (age+age2+sex; age+ age2). We evaluated whether additional model terms beyond the base model were needed using an a priori cut‐off of 1% variance improvement in adjusted R2 over and above the base model. We examined rates of low test performance defined as performance below ‐1 SD in independent validation samples (n = 167 concordant CU, n = 64 mild cognitive impairment (MCI), n = 14 dementia). Rates are considered significantly different than expected when 95% confidence intervals (CIs) do not include the expected 14.7% base rate frequency.ResultNo additional potential model terms met our a priori cut‐off for inclusion beyond the base model (see Table 2), including other quadratic and cubic terms or interactions, device type, response input type, potential session interference, and national area deprivation index (ADI available in subset; N = 776). Application of norms showed expected rates of low test performance among CU participants (95% CI includes expected base rate) and significantly greater than expected rates of low test performance for all variables in MCI (e.g., 62.5% for composite) and dementia (e.g., 71.4% for composite; see Table 3).ConclusionTypical normative models appear appropriate for remote self‐administered measures and are sensitive to cognitive impairment. Device type and response input did not explain enough variance to warrant inclusion in normative models but are important for individual level interpretation. Future work will improve representation of individuals from under‐represented groups.
Clinical criteria for a limbic‐predominant amnestic neurodegenerative syndrome highly associated with TDP‐43 and slow clinical progression
Graff‐Radford, Jonathan , Przybelski, Scott A. , Wiste, Heather J. , Reichard, Ross R., Fields, Julie A. , Nelson, Peter T. , Lowe, Val J. , Petersen, Ronald C. , Corriveau‐Lecavalier, Nick , Botha, Hugo , Switzer, Aaron , Murray, Melissa E. , Dickson, Dennis W. , Nguyen, Aivi T. , Ramanan, Vijay K. , McCarter, Stuart J. , Boeve, Bradley F. , Machulda, Mary M. , Stricker, Nikki H. , Grothe, Michel J. , Knopman, David S. , Jack, Clifford R. , Jones, David T.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.084087 Get It

AbstractBackgroundLimbic‐predominant age‐related TDP‐43 encephalopathy (LATE) is a neuropathologically‐defined disease, and it is frequently comorbid with Alzheimer’s disease neuropathological change (ADNC). However, the neurological syndrome associated with LATE neuropathological change (LATE‐NC) is not defined. We propose a set of clinical criteria for a limbic‐predominant amnestic neurodegenerative syndrome (LANS) that is highly associated with LATE‐NC. These criteria assess degree of certainty (highest, high, moderate, low) based on features that are measurable in vivo, including older age at evaluation, a mild clinical syndrome, impaired semantic knowledge, disproportionate hippocampal atrophy, limbic hypometabolism, absence of neocortical degeneration patterns and low likelihood of neocortical tau. We operationalized these criteria using two large datasets with clinical and pathologic outcomes.MethodWe screened autopsied patients from Mayo Clinic and ADNI cohorts and applied the LANS criteria to those with an antemortem predominant amnestic syndrome (Mayo, n = 165; ADNI, n = 53). We compared frequencies of neuropathological diagnoses across LANS likelihoods, compared longitudinal CDR‐SB trajectories across LANS likelihoods, and stratified ADNC/LATE‐NC patients according to their LANS likelihood and compared their longitudinal CDR‐SB trajectories to those with ADNC or LATE‐NC.ResultADNC, ADNC/LATE‐NC and LATE‐NC accounted for 35%, 37% and 4% of cases in the Mayo cohort, respectively, and 30%, 22%, and 9% of cases in the ADNI cohort, respectively (Fig. 1). ADNC cases had the lowest LANS likelihoods, LATE‐NC patients had the highest likelihoods, and ADNC/LATE‐NC patients had intermediate likelihoods. Patients with high LANS likelihoods had a milder and slower clinical course and more severe temporo‐limbic degeneration compared to those with low likelihoods (Fig. 2). ADNC/LATE‐NC patients with higher likelihoods had more temporo‐limbic degeneration and a slower rate of cognitive decline, and those with lower likelihoods had more lateral temporo‐parietal degeneration and a faster rate of cognitive decline (Fig. 3).ConclusionThe implementation of LANS criteria has implications for disambiguating the different driving etiologies of progressive amnestic presentations in older age to guide prognosis, treatment, and clinical trial design and enrollment. The development of in vivo biomarkers specific to TDP‐43 pathology are needed to further refine molecular associations between LANS and LATE‐NC and precise antemortem diagnoses of LATE.
Frequency of Spondyloarthritis Symptoms Among US Patients With Inflammatory Bowel Disease: A Cross‐Sectional Multi‐Center Study
Ermann, Joerg , Hong, Simon , Stahly, Andrew , Malik, Fardina , Click, Benjamin , Way, Anna, Davis, John M. , Shmais, Manar, Raffals, Laura E., Silfen, Alexa , Dharia, Ishaan , Bhattacharya, Abhik , Moghaddam, Bahar, Mains, Trayton, Kurland, Jayde E., Weisman, Michael H., Davis, John M , Silfen, Alexa , Kuhn, Kristine A , Ermann, Joerg , Dalal, Rahul S. , Scott, Frank I. , Way, Anna, Raffals, Laura E. , Jan, Reem , Rubin, David T. , Patel, Sheena , Kuhn, Kristine A. , Weisman, Michael H.

Mayo Clinic

Arthritis Care & Research | January 3, 2025 | Volume: 77 | Issue: 6 | Pages: 777-784

10.1002/acr.25493 | PMID 39748206 Get It

ObjectiveSpondyloarthritis (SpA) is the most common extraintestinal manifestation of inflammatory bowel disease (IBD). The application of screening tools to detect SpA in patients with IBD may lead to earlier recognition of SpA and affect treatment decisions.MethodsA combination of two previously described SpA screening questionnaires, the Detection of Arthritis in Inflammatory Bowel Disease (DETAIL) and IBD Identification of Spondyloarthritis Questionnaire (IBIS‐Q), was administered to consecutive patients with IBD attending IBD specialty clinics in six US academic medical centers. Demographic data, IBD, and rheumatology history were extracted by chart review.ResultsA total of 669 patients were analyzed. The median age was 40 years (interquartile range [IQR] 30–54) with a median disease duration of 12 years (IQR 6–22) and moderate to severe IBD based on medication exposure and history of bowel surgery. A total of 81 patients (12%) carried a diagnosis of an inflammatory rheumatic disease, whereas 75 (11%) had consulted a rheumatologist during the previous year. Using published cutoffs, 180 out of 669 patients (27%) screened positive with DETAIL, 266 (40%) with IBIS‐Q, and 275 (41%) with either questionnaire. Axial symptoms were more frequently reported than peripheral musculoskeletal complaints. Notably, 189 out of 275 (69%) screen‐positive patients had neither a documented inflammatory rheumatic disease diagnosis nor a visit with a rheumatologist within the past year.ConclusionA substantial proportion of patients with IBD have symptoms suggestive of SpA, and many of these may have undiagnosed SpA. The IBIS‐Q questionnaire appears to identify more potential SpA cases than DETAIL. Strategies are needed to prioritize rheumatology consultations for those patients with IBD who are most likely to benefit.